Pregabalin

Generic Name
Pregabalin
Brand Names
Lyrica, Pregabalin Accord, Pregabalin Pfizer, Pregabalin Sandoz, Pregabalin Mylan, Pregabalin Zentiva
Drug Type
Small Molecule
Chemical Formula
C8H17NO2
CAS Number
148553-50-8
Unique Ingredient Identifier
55JG375S6M
Background

Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels. Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release). It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.

Indication

Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.

Associated Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Epilepsies, Fibromyalgia, Generalized Anxiety Disorder, Neuropathic Pain, Partial-Onset Seizures, Peripheral Neuropathic Pain, Peripheral neuropathy, Postherpetic Neuralgia
Associated Therapies
-
Clinical Trials
Related News

Pregabalin for the Treatment of Vulvodynia

Phase 2
Terminated
Conditions
Vulvar Vestibulitis
Vulvodynia
Interventions
Drug: pregabalin
First Posted Date
2009-03-02
Last Posted Date
2021-07-19
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
16
Registration Number
NCT00853229
Locations
🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

The Effects of Peri-Operative Pregabalin on Post-Operative Pain Following Breast Cancer Surgery With Axillary Node Dissection: A Pilot Study

First Posted Date
2009-02-27
Last Posted Date
2014-03-07
Lead Sponsor
Nova Scotia Health Authority
Target Recruit Count
70
Registration Number
NCT00852683
Locations
🇨🇦

Capital District Health Authority, Halifax, Nova Scotia, Canada

Pregabalin and Orofacial Neuropathic Pain

Phase 2
Terminated
Conditions
Neuropathic Pain
Orofacial Pain
Interventions
Drug: placebo
Drug: pregabalin
First Posted Date
2009-02-27
Last Posted Date
2015-06-03
Lead Sponsor
University of Toronto
Target Recruit Count
1
Registration Number
NCT00852436
Locations
🇨🇦

Dr. P. Watson's office, Etobicoke, Ontario, Canada

🇨🇦

University of Toronto, Toronto, Ontario, Canada

Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA

Completed
Conditions
Neuropathic Pain
Interventions
Drug: Pregabalin
First Posted Date
2009-02-13
Last Posted Date
2021-02-10
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
691
Registration Number
NCT00843284

Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain

First Posted Date
2009-02-06
Last Posted Date
2011-07-14
Lead Sponsor
Forest Laboratories
Target Recruit Count
458
Registration Number
NCT00838799
Locations
🇺🇸

Forest Investigative Site, Tacoma, Washington, United States

Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia

Phase 3
Completed
Conditions
Fibromyalgia
Interventions
Drug: Pregabalin
Drug: Placebo
First Posted Date
2009-01-27
Last Posted Date
2021-01-25
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
498
Registration Number
NCT00830167
Locations
🇯🇵

Pfizer Investigational Site, Yokohama, Japan

Pregabalin in the Prevention of Postoperative Delirium and Pain

Phase 3
Completed
Conditions
Delirium
Pain
Interventions
Other: Sugar pill
Drug: Pregabalin
First Posted Date
2009-01-09
Last Posted Date
2012-01-10
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
240
Registration Number
NCT00819988
Locations
🇨🇦

The Ottawa Hospital, Ottawa, Ontario, Canada

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

First Posted Date
2008-12-10
Last Posted Date
2021-01-26
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
731
Registration Number
NCT00806026
Locations
🇬🇧

Pfizer Investigational Site, Reading Berks, United Kingdom

Evaluation of Pregabalin in Idiopathic Small Fiber Neuropathy

Not Applicable
Terminated
Conditions
Small-Fiber Neuropathy
Interventions
Drug: Placebo
Drug: Pregabalin
First Posted Date
2008-11-07
Last Posted Date
2017-08-28
Lead Sponsor
University of Alberta
Target Recruit Count
3
Registration Number
NCT00787462
Locations
🇨🇦

University of Alberta Hospital, Edmonton, Alberta, Canada

A Study for Treatment of Pain in Patients With Diabetic Neuropathy.

First Posted Date
2008-11-05
Last Posted Date
2012-05-31
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
273
Registration Number
NCT00785577
Locations
🇵🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy